Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold
retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection
in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE
to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should
non-selectively stop the RPE leakage.